FDA approves removal of boxed-warning risk statements from three more estradiol patches
The rewrite of menopausal hormone therapy labeling now covers nine products.
HHS announced Oct. 30 that FDA approved updated labeling for three more menopausal hormone therapy products, all estradiol transdermal patches from two applicants, removing statements on cardiovascular disease, breast cancer and probable dementia from the boxed warning section [1]. The action follows February 2026 label changes for six such products; 29 companies have submitted proposed labeling changes since FDA began engaging manufacturers in November 2025 [1][2].
STAT investigation: U.S. firm sent women abroad for “three-parent IVF” on scant evidence
An eight-month investigation traces a mitochondrial replacement business run from the Chicago suburbs.
STAT reported Nov. 2 that International Fertility Group of North America, a medical-tourism facilitator in Northbrook, Ill., arranged mitochondrial replacement therapy at partner clinics in Albania and Georgia, a procedure STAT describes as effectively illegal in the U.S. and marketed for infertility despite scant evidence of safety or efficacy [3]. The company’s website claimed 34 babies born as of February 2025 and a pregnancy success rate above 50 percent without substantiation; one patient profiled paid more than $30,000 and did not become pregnant [3]. IFG paused new MRT patients after STAT’s July inquiries and later removed all mention of MRT from its website [3].
Scientific Reports on hold in PubMed while NLM re-evaluates the journal
The Springer Nature mega-journal has published more than 41,000 articles this year.
Retraction Watch reported Oct. 30 that MEDLINE indexing and PubMed Central archiving of new Scientific Reports articles are paused while the National Library of Medicine reviews the journal, according to chief editor Rafal Marszalek, who did not say what prompted the review [4]. The most recent Scientific Reports articles in PubMed were published Sept. 15; the journal’s site lists 41,122 articles this year, against 28,593 indexed in PubMed [4].
CMS finalizes rule tightening oversight of organ procurement organizations
High-performing OPOs can compete for more territory; noncompliant ones face immediate decertification.
CMS finalized a rule Oct. 30 that lets high-performing organ procurement organizations compete for multiple donation service areas, defines “unsound medical practices” to clarify when CMS may immediately decertify a noncompliant OPO, and requires OPOs to track what happens to organs sent for research [5]. An OPO’s medical director must now hold a license in at least one state or territory the OPO serves [5]. HHS said more than 49,000 transplants were performed in the U.S. in 2025 while over 100,000 Americans are waiting [5].
Digest references
U.S. Department of Health and Human Services. “Trump Administration Delivers for Women with Major Advances in Menopause Care.” HHS press release, Oct. 30, 2026. hhs.gov
Bascom E. “HHS updates safety labels for three more menopausal hormone therapy products.” Healio, Oct. 30, 2026. healio.com
Molteni M. “Women travel thousands of miles for a reproductive moonshot. Scientists say they’ve been misled.” STAT, Nov. 2, 2026. statnews.com
Travis K. “Scientific Reports on hold in PubMed while NLM reevaluates journal.” Retraction Watch, Oct. 30, 2026. retractionwatch.com
Centers for Medicare & Medicaid Services. “CMS Finalizes Rule to Help More Organs Reach Patients and Strengthen Accountability for Organ Procurement Organizations.” HHS press release, Oct. 30, 2026. hhs.gov
